
Adam Hanina, MBA MPhil
CEO, AiCure
Disclosures: Adam Hanina

I have an interest in AiCure that could be perceived as a possible conflict of interest in the context of this presentation. The relationships are summarized below:

Primary Investigator
Shareholder
Salaried employee
1:1 VS 1:Many
## Medication monitoring landscape

<table>
<thead>
<tr>
<th></th>
<th>PILL COUTNS</th>
<th>TEXT MESSAGING</th>
<th>DIGITAL CAPS</th>
<th>MICROCHIPS-ON-PILLS</th>
<th>BIOASSAYS</th>
<th>DIRECTLY OBSERVED THERAPY (DOT)</th>
<th>AIVIEW (AUTOMATED DOT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REAL-TIME MONITORING</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACCURACY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROTOCOL TRAINING</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTERVENTION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDENTIFICATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCALABLE/EASY TO IMPLEMENT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIKABLE / EASE OF USE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROUTES OF ADMINISTRATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1:1 VDOT, MDOT

1: MANY
Flow of Data

1. AiView
   Store and forward device.

2. Secure transmission of encrypted data to servers.

3. Web-based dashboard allows secure real-time access to data & notifications.

4. Automated and personal follow-ups enabled.

HIPAA-compliant
Disaster recovery
Role-based secure access
Encrypted data
PCI compliant
Trial achieved high adherence with Automated DOT

(86.8% medication adherence when self-reporting and in clinic dosing included)

Automated DOT Adherence

Average medication adherence in patients with schizophrenia (range from 20%-89%)*

Number of days in trial

Average Adherence

0%  0  30  60  90  120  150  180

0%  50%  100%

76.7%

50%


Medication adherence data captured from the AiView system in a Phase 2 schizophrenia clinical trial for a top 10 pharmaceutical company. Duration of enrollment = up to 6 months

N=53

Data Generated 05/01/2014
Award-winning Facial Recognition To Confirm Medication Adherence

Medication reminder on the smartphone prompts the patient to take their weekly dose

Patient is identified

Medication is identified

Ingestion is confirmed

Real-time encrypted data are automatically transmitted to a centralized dashboard

Deviation from protocol (nonadherence) is automatically flagged for escalation
Security measures
Multiple languages will be offered: English, Mandarin, Tagalog, Bengali, Spanish

- Medication Reminder
- Patient Identification
- Medication ID
- Confirm Ingestion
Common questions

Is the Automated DOT System like taking a picture?

Can the system be tricked?

Isn’t this too big brother?

Does the manufacturing process need to be changed?

How is patient privacy maintained?
Global applications

2018 Forecast**
4.5 billion smartphone subscriptions

2012**
1.2 billion smartphone subscriptions

*ICT Facts and Figures 2013. Published by ITU (international telecomm union)
**Ericsson Mobility Report June 2013
What are the future implications of Automated DOT

1) Technology is accepted and has high feasibility - even among a challenging population.

2) Strong potential with latent TB (3HP) due to low-cost and accuracy.

3) Automated DOT could increase treatment initiation and completion.

4) Convenience as Automated DOT is available on any smartphone (majority of latent TB cases in the US among foreign-born; most have smartphones, most work).

5) Adherence data can be easily integrated into existing electronic medical records.

6) Global applications.

7) Micro-incentive structures (rewards redeemable through cell phone - extra minutes, etc).